ClinicalTrials.gg
RecruitingNCT07945470SIMPLYUpdated Nov 18, 2026

Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma

An interventional study of Simulation-Free Single-Fraction Radiation Therapy (4 Gy × 1) in Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma and Follicular Lymphoma, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada — 5 open to participants now, 13 under way, 2 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Canada.

Planned enrollment
20th of 30
60 · median 87
Started
2026
with 1 other
No phase
Only one
of the 33
Primary completion
2028-12
later than 9 of 12 live
Registered
33rd of 33
by date

Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada, this one is the 20th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2026, is the only one with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 33rd registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

5 of the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada, or all of them as a file.
02

Study summary

This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.

The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.

Read the detailed description

This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.

Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.

On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.

The study includes two cohorts:

Participants with orbital or ocular adnexal indolent B-cell lymphoma.

Participants with non-orbital indolent B-cell lymphoma.

If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.

The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.

Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.

03

Conditions studied

  • Indolent B-Cell Non-Hodgkin Lymphoma
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma (MCL)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed indolent B-cell lymphoma, including marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma grades 1-2, small lymphocytic lymphoma, or mantle cell lymphoma.
  • Disease requiring focal radiation therapy with 4 Gy delivered in one fraction for local control or symptom relief.
  • Lesion anatomy suitable for single-fraction radiation therapy and simulation-free, CBCT-guided treatment delivery, as determined by the treating radiation oncologist.
  • Available diagnostic CT imaging suitable for contouring and dose calculation that encompasses the full intended target and relevant organs at risk:
  • Obtained within 2 months before treatment for orbital or ocular adnexal disease.
  • Obtained within 6 weeks before treatment for non-orbital disease.
  • (ECOG) performance status of 0-3, with the ability to tolerate treatment positioning and delivery.
  • Localized or advanced-stage disease is permitted, provided the target lesion is appropriate for focal treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnostic imaging that does not meet the minimum quality requirements for treatment planning or falls outside the required time window.
  • Disease anatomy unsuitable for simulation-free delivery, such as inability to maintain stable positioning, excessive motion, or inadequate CBCT visualization.
  • Prior radiation therapy to the same site if re-irradiation using the study workflow is considered clinically inappropriate.
  • Bulky disease greater than 6 centimeters for which single-fraction 4 Gy radiation therapy is unlikely to provide adequate local control, as determined by the treating physician.
  • Requirement for urgent systemic therapy because of widespread or symptomatic disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Simulation-Free Single-Fraction Radiation Therapy

    Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment.

    Radiation: Simulation-Free Single-Fraction Radiation Therapy (4 Gy × 1)

Interventions

  • RadiationSimulation-Free Single-Fraction Radiation Therapy (4 Gy × 1)

    Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.

    Also known as: Ultra-Low-Dose Radiation Therapy, CBCT-Guided Adaptive Radiation Therapy, Diagnostic CT-Based Radiation Treatment Planning

06

What researchers measure

Primary outcomes

  1. Successful Completion of Simulation-Free Radiation Therapy

    Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation.

    Time frame: Periprocedural (single radiation treatment session)

Secondary outcomes

  1. Time From Radiation Oncology Consultation to Treatment

    Number of calendar days between the radiation oncology consultation date and the date of radiation treatment.

    Time frame: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks

  2. Same-Day Treatment

    Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation.

    Time frame: Day 1 (date of radiation oncology consultation)

  3. Total On-Couch Time

    Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery.

    Time frame: Periprocedural (single radiation treatment session)

  4. Number of Hospital Visits

    Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow.

    Time frame: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks

  5. CT Simulation Avoided

    Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment.

    Time frame: Periprocedural (through completion of the single radiation treatment session)

  6. Reasons for Simulation-Free Workflow Failure

    Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan.

    Time frame: From treatment planning through radiation treatment completion, up to 4 weeks

  7. Clinician-Graded Treatment-Related Toxicity

    Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported.

    Time frame: Baseline, 2-4 weeks, and 3 months after treatment

  8. Ocular Surface Disease Index Score

    Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment.

    Time frame: Baseline, 2-4 weeks, and 3 months after treatment

  9. Head and Neck Quality-of-Life Symptoms

    Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites.

    Time frame: Baseline, 2-4 weeks, and 3 months after treatment

  10. Index Symptom Severity

    Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom.

    Time frame: Baseline, 2-4 weeks, and 3 months after treatment

  11. Local Control of the Treated Site

    Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination.

    Time frame: 6 months after radiation treatment

  12. Retreatment of the Treated Site

    Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site.

    Time frame: Within 12 months after radiation treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 18, 2026
StartActual
Oct 9, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945470
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Oct 9, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Mahmood AminiLari, PhD
Contact
mahmood.aminilari@uhn.ca
4169464501 ext. 6522

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion